BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
117 results:

  • 1. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
    Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Blockade of isoprenoids biosynthesis by simvastatin induces autophagy-mediated cell death via downstream c-Jun N-terminal kinase activation and cell cycle dysregulation in canine T-cell lymphoma cells.
    Kobayashi K; Baba K; Kambayashi S; Okuda M
    Res Vet Sci; 2024 Mar; 169():105174. PubMed ID: 38340381
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
    Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
    J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Gupta S; Kohorst M; Alkhateeb HB
    Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
    Al-Sawaf O; Ligtvoet R; Robrecht S; Stumpf J; Fink AM; Tausch E; Schneider C; Boettcher S; Mikusko M; Ritgen M; Schetelig J; von Tresckow J; Vehling-Kaiser U; Gaska T; Wendtner CM; Chapuy B; Fischer K; Kreuzer KA; Stilgenbauer S; Staber P; Niemann C; Hallek M; Eichhorst B
    Nat Med; 2024 Jan; 30(1):240-248. PubMed ID: 38071379
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Sharing Experience with Anaplastic lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.
    Gridelli C; Tiseo M; Cortinovis DL; Migliorino MR; Barbieri V; Bironzo P; Bearz A; Attili I; de Marinis F
    Curr Oncol; 2023 Nov; 30(11):10033-10042. PubMed ID: 37999149
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
    Oikonomou A; Valsecchi L; Quadri M; Watrin T; Scharov K; Procopio S; Tu JW; Vogt M; Savino AM; Silvestri D; Valsecchi MG; Biondi A; Borkhardt A; Bhatia S; Cazzaniga G; Fazio G; Bardini M; Palmi C
    Biochem Pharmacol; 2023 Nov; 217():115809. PubMed ID: 37717691
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Cancer-specific apoptosis induction in canine lymphoma cell lines by the endocytosis inhibitor dynasore.
    Suemura M; Miyata H; Kawamura R; Takahashi S; Igase M; Mizuno T; Ohama T; Shibutani S; Iwata H
    J Vet Med Sci; 2023 Aug; 85(8):820-827. PubMed ID: 37407446
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
    Schnuchel A; Radcke C; Theobald L; Doeding S
    PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. CAR T-cell therapy in large B cell lymphoma.
    Boardman AP; Salles G
    Hematol Oncol; 2023 Jun; 41 Suppl 1(Suppl 1):112-118. PubMed ID: 37294963
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Cost‑Effectiveness of Lorlatinib in First-Line treatment of Adult Patients with Anaplastic lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Hydrocortisone to reduce dexamethasone-induced neurobehavioral side-effects in children with acute lymphoblastic leukaemia-results of a double-blind, randomised controlled trial with cross-over design.
    van Hulst AM; van den Akker ELT; Verwaaijen EJ; Fiocco M; Rensen N; van Litsenburg RRL; Pluijm SMF; Zwaan CM; van Santen HM; Pieters R; Evers AWM; Grootenhuis MA; van den Heuvel-Eibrink MM
    Eur J Cancer; 2023 Jul; 187():124-133. PubMed ID: 37149961
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.
    Ivanov AV; Alecsa MS; Popescu R; Starcea MI; Mocanu AM; Rusu C; Miron IC
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902091
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: a clinicopathological and molecular analysis].
    Jin YP; Wang L; Wang Y; Wu DY; Zhang H; Xia QX
    Zhonghua Bing Li Xue Za Zhi; 2022 Dec; 51(12):1229-1234. PubMed ID: 36480831
    [No Abstract]    [Full Text] [Related]  

  • 16.
    Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J
    Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel.
    Cutini I; Puccini B; Fabbri A; Santi R; Gozzini A; Nozzoli C; Boncompagni R; Innocenti C; Saccardi R
    Transpl Immunol; 2022 Dec; 75():101719. PubMed ID: 36116729
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. [Nodular lymphocyte predominant Hodgkin lymphoma (paragranuloma of Poppema) in children: Case report, review of the literature and treatment].
    Wilgenhof K; Théate I; Devalck C; Forsyth R; Dehou MF
    Ann Pathol; 2023 Jan; 43(1):39-44. PubMed ID: 36008237
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeting molecular alterations in non-small-cell lung cancer: what's next?
    López-Castro R; García-Peña T; Mielgo-Rubio X; Riudavets M; Teixidó C; Vilariño N; Couñago F; Mezquita L
    Per Med; 2022 Jul; 19(4):341-359. PubMed ID: 35748237
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
    Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.